我的购物车

Human OX40 / TNFRSF4 / CD134 Protein, His Tag (MALS verified)

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

  • 分子别名(Synonym)

    TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

  • 表达区间及表达系统(Source)

    Human OX40 Protein, His Tag (OX0-H5224) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # P43489-1).

    Predicted N-terminus: Leu 29

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    OX40 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 22.0 kDa. The protein migrates as 35-45 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    90% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    OX40 SDS-PAGE

    Human OX40 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    OX40 SEC-MALS

    The purity of Human OX40 Protein, His Tag (Cat. No. OX0-H5224) is more than 85% and the molecular weight of this protein is around 32-44 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     OX40 ELISA

    Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL (100 μL/well) can bind Human OX40 Ligand, Fc Tag, premium grade (Cat. No. OXL-H5266) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  OX40 ELISA

    Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human OX40 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol
  •  OX40 ELISA

    Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay, Routinely tested).

    Protocol
  • 活性(Bioactivity)-BLI

     OX40 BLI

    Loaded Human OX40 Ligand, His Tag (Cat. No. OXL-H52Q8) on AR2G Biosensor, can bind Human OX40 Protein, His Tag (Cat. No. OX0-H5224) with an affinity constant of 0.15 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  OX40 BLI

    Loaded Anti-OX40 MAb(Human IgG1) on AHC Biosensor, can bind Human OX40 Protein, His Tag (Cat. No. OX0-H5224) with an affinity constant of 6.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

前沿进展

 
药物研发进展
  • 英文全称:

    Tumor necrosis factor receptor superfamily member 4

  • 中文全称:

    肿瘤坏死因子受体超家族成员4

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    28 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍